SCHEMBL2008677

SCHEMBL2008677

OC1CCN(c2ncccc2Br)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 3/20 0.46
KMT2A Q03164 1/20 0.46
PIM1 P11309 2/20 0.43
KCNMA1 Q12791 1/20 0.43
PDE10A Q9Y233 2/20 0.42
KDM4E B2RXH2 1/20 0.42
RECQL P46063 1/20 0.42
SMO Q99835 1/20 0.41
PIK3CA P42336 1/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
CDC7 O00311 1/20 0.41
PLK4 O00444 1/20 0.41
CHEK1 O14757 1/20 0.41
AURKA O14965 1/20 0.41
PDPK1 O15530 1/20 0.41
JAK2 O60674 1/20 0.41
ROCK2 O75116 1/20 0.41
PAK4 O96013 1/20 0.41
CHEK2 O96017 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4880417 0.83 PDE10A (0.39) MALT1KMT2APIM1PDE10ATRPV1
SCHEMBL4879872 0.81 KDM4E (0.60) MALT1KMT2AKDM4ERECQLDYRK1A
SCHEMBL27703385 0.80 CYP1A2 (0.49) MALT1KMT2AKDM4EMAPK1TRPV1
SCHEMBL20406252 0.80 CYP1A2 (0.53) KMT2AKDM4EMAPK1TRPV1
SCHEMBL3435694 0.80 GRIN2D (0.51) MALT1KMT2APIM1KCNMA1PDE10A
SCHEMBL3436511 0.80 SMO (0.53) MALT1KMT2APIM1KCNMA1PDE10A
SCHEMBL10324446 0.80 MALT1 (0.59) MALT1SMOTRPV1
SCHEMBL1728915 0.78 KMT2A (0.50) MALT1KMT2AKDM4ERECQLTRPV1
SCHEMBL31312203 0.78 LMNA (0.39) MALT1KMT2APIM1PDE10AKDM4E
SCHEMBL24377504 0.77 MALT1 (0.57) MALT1KDM4ERECQLTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964602-B2 Biaryl compounds useful as agonists of the Gpr38 receptor GLAXO GROUP LIMITED (GB) 2011-06-21 US disclosed
EP-1960390-B1 BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR GLAXO GROUP LTD (GB) 2010-07-21 EP disclosed
US-20080306083-A1 Biaryl Compounds Useful as Agonists of the Gpr38 Receptor GLAXO GROUP LIMITED 2008-12-11 US disclosed
EP-1960390-A1 BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR GLAXO GROUP LIMITED (GB) 2008-08-27 EP disclosed
WO-2007065669-A1 BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR GLAXO GROUP LIMITED (GB) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306083-A1 Biaryl Compounds Useful as Agonists of the Gpr38 Receptor GPR88, GPR68, GPBAR1 MALT1 1182/4885KMT2A 3883/4885PIM1 4768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.